Entellus Medical, Inc. (NASDAQ:ENTL) – Equities researchers at William Blair lifted their FY2017 EPS estimates for Entellus Medical in a report released on Thursday. William Blair analyst K. Krum now anticipates that the medical technology company will post earnings of ($1.33) per share for the year, up from their prior estimate of ($1.53). William Blair also issued estimates for Entellus Medical’s Q4 2017 earnings at ($0.45) EPS, Q1 2018 earnings at ($0.34) EPS, Q2 2018 earnings at ($0.27) EPS, Q3 2018 earnings at ($0.30) EPS, Q4 2018 earnings at ($0.24) EPS and FY2018 earnings at ($1.15) EPS.
Entellus Medical (NASDAQ:ENTL) last posted its quarterly earnings data on Thursday, August 3rd. The medical technology company reported ($0.37) EPS for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.03). The business had revenue of $22.10 million during the quarter, compared to the consensus estimate of $21.87 million. Entellus Medical had a negative return on equity of 60.10% and a negative net margin of 31.24%. The company’s revenue for the quarter was up 18.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.27) earnings per share.
COPYRIGHT VIOLATION NOTICE: “FY2017 EPS Estimates for Entellus Medical, Inc. (ENTL) Increased by William Blair” was published by Community Financial News and is the property of of Community Financial News. If you are reading this story on another site, it was stolen and republished in violation of United States and international copyright and trademark legislation. The legal version of this story can be viewed at https://www.com-unik.info/2017/11/06/fy2017-eps-estimates-for-entellus-medical-inc-entl-increased-by-william-blair.html.
Several other research firms have also recently weighed in on ENTL. Zacks Investment Research upgraded shares of Entellus Medical from a “sell” rating to a “buy” rating and set a $23.00 target price for the company in a research report on Monday, October 9th. BidaskClub cut shares of Entellus Medical from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, July 25th. Piper Jaffray Companies restated a “buy” rating on shares of Entellus Medical in a research report on Wednesday, July 12th. Finally, Canaccord Genuity restated a “hold” rating and issued a $17.00 price objective on shares of Entellus Medical in a research report on Tuesday, October 17th. Two analysts have rated the stock with a sell rating, three have issued a hold rating and four have issued a buy rating to the company’s stock. Entellus Medical has an average rating of “Hold” and a consensus price target of $21.17.
Shares of Entellus Medical (NASDAQ ENTL) opened at $17.24 on Monday. The company has a debt-to-equity ratio of 0.19, a current ratio of 3.87 and a quick ratio of 3.53. Entellus Medical has a 1-year low of $11.47 and a 1-year high of $20.34.
Several large investors have recently modified their holdings of ENTL. Bank of America Corp DE raised its stake in Entellus Medical by 53.8% during the first quarter. Bank of America Corp DE now owns 7,418 shares of the medical technology company’s stock worth $102,000 after buying an additional 2,594 shares during the last quarter. Nationwide Fund Advisors raised its stake in Entellus Medical by 61.7% during the second quarter. Nationwide Fund Advisors now owns 6,903 shares of the medical technology company’s stock worth $114,000 after buying an additional 2,635 shares during the last quarter. First Mercantile Trust Co. raised its stake in Entellus Medical by 45.3% during the second quarter. First Mercantile Trust Co. now owns 8,206 shares of the medical technology company’s stock worth $136,000 after buying an additional 2,557 shares during the last quarter. Parametric Portfolio Associates LLC increased its stake in Entellus Medical by 5.6% in the first quarter. Parametric Portfolio Associates LLC now owns 10,888 shares of the medical technology company’s stock valued at $150,000 after purchasing an additional 573 shares in the last quarter. Finally, The Manufacturers Life Insurance Company increased its stake in Entellus Medical by 61.7% in the second quarter. The Manufacturers Life Insurance Company now owns 11,881 shares of the medical technology company’s stock valued at $196,000 after purchasing an additional 4,533 shares in the last quarter. Institutional investors own 70.25% of the company’s stock.
In other news, VP Timothy B. Petrick sold 2,000 shares of the firm’s stock in a transaction that occurred on Friday, September 22nd. The shares were sold at an average price of $18.00, for a total transaction of $36,000.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, VP Stephen R. Paidosh sold 25,000 shares of the firm’s stock in a transaction that occurred on Wednesday, September 13th. The stock was sold at an average price of $17.54, for a total transaction of $438,500.00. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 92,150 shares of company stock worth $1,740,652. 7.70% of the stock is owned by insiders.
About Entellus Medical
Entellus Medical, Inc is a medical technology company. The Company is focused on delivering patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis in both adult and pediatric patients. Its three core product lines, XprESS Multi-Sinus Dilation Systems, MiniFESS Surgical Instruments, and FocESS Imaging & Navigation, are designed to enable ear, nose and throat (ENT), physicians to perform a range of procedures in the ENT physician office and to simplify operating room-based treatment.
What are top analysts saying about Entellus Medical Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Entellus Medical Inc. and related companies.